Georg Bjarnason
Overview
Explore the profile of Georg Bjarnason including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
373
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shrem N, Beltran-Bless A, Ghosh S, Tajzler C, Wood L, Kollmannsberger C, et al.
Cancers (Basel)
. 2025 Feb;
17(3).
PMID: 39941888
Background: Ipilimumab and nivolumab (ipi/nivo) improved overall survival (OS) compared to sunitinib in the pivotal Checkmate 214 trial of metastatic renal cell carcinoma (mRCC) with International Metastatic RCC Database Consortium...
2.
Soytas M, Dragomir A, Sawaya G, Hesswani C, Tanguay M, Finelli A, et al.
BJU Int
. 2024 Dec;
PMID: 39631366
Objective: To evaluate and compare the outcomes of patients with localised renal cell carcinoma (RCC) with and without sarcomatoid features and the impact of this on cancer recurrence and survival....
3.
Cardenas L, Ghosh S, Finelli A, Wood L, Kollmannsberger C, Basappa N, et al.
JCO Glob Oncol
. 2023 Nov;
9:e2300271.
PMID: 37992270
Purpose: Standard-of-care therapies for metastatic renal cell carcinoma (mRCC) have greatly evolved. However, the availability of emerging options in global health care systems can vary. We sought to describe the...
4.
Dragomir A, Nazha S, Tanguay S, Breau R, Bhindi B, Rendon R, et al.
Eur Urol Focus
. 2021 Nov;
8(6):1703-1710.
PMID: 34736870
Background: Treatment options for metastatic renal cell carcinoma (mRCC) include cytoreductive nephrectomy (CN) and systemic therapy (ST). Results from the CARMENA and SURTIME trials suggest that CN before ST may...
5.
Patel J, Jiang C, Owzar K, Mulkey F, Luzum J, Mamon H, et al.
Pharmacogenet Genomics
. 2021 Jun;
31(9):215-220.
PMID: 34149004
There is a lack of pharmacogenetic predictors of outcome in gastric cancer patients. The aim of this study was to assess previously identified candidate genes associated with 5-fluorouracil (5-FU), cisplatin,...
6.
Canil C, Kapoor A, Basappa N, Bjarnason G, Bosse D, Dudani S, et al.
Can Urol Assoc J
. 2021 Apr;
15(4):84-97.
PMID: 33830005
No abstract available.
7.
Shiff B, Breau R, Patel P, Mallick R, Tanguay S, So A, et al.
J Urol
. 2020 Nov;
205(1):84-85.
PMID: 33169653
No abstract available.
8.
Shiff B, Breau R, Patel P, Mallick R, Tanguay S, So A, et al.
J Urol
. 2020 Jul;
205(1):78-85.
PMID: 32614274
Purpose: The time between radiographic identification of a renal tumor and surgery can be concerning for patients and clinicians due to fears of tumor progression while awaiting treatment. This study...
9.
Hotte S, Kapoor A, Basappa N, Bjarnason G, Canil C, Conter H, et al.
Can Urol Assoc J
. 2019 Oct;
13(10):343-354.
PMID: 31603413
No abstract available.
10.
Saleeb R, Farag M, Ding Q, Downes M, Bjarnason G, Brimo F, et al.
Am J Pathol
. 2019 Aug;
189(10):2046-2060.
PMID: 31381885
Papillary renal cell carcinoma (PRCC) is the most common type of RCC in end-stage kidney disease (ESKD). Papillary adenoma (PA) is a small benign lesion morphologically similar to PRCC and...